Regeneron's (REGN) Recovery and Dupixent Strength Support BMO's Outperform Rating

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is included among the 14 Best US Stocks to Buy for Long Term.

On December 4, BMO Capital analyst Evan Seigerman boosted the firm’s price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $850 from $725 and maintained an Outperform rating on the stock. The analyst noted that the stock has surged by over 50% after its itepekimab setback in June, as the company’s efforts to clear regulatory issues start to pay off. BMO also expects stronger results from Dupixent and a slower decline in 2mg Eylea, which helped justify the higher price target.

In the third quarter of 2025, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)’s Eylea net sales in the US increased 10% to $431 million, but combined sales with the original version fell by 28% on a YoY basis to $1.11 billion. The company’s overall revenue for the quarter came in at $3.75 billion, which showed a modest growth of 1% compared to the same period last year.

In other news, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Tessera Therapeutics are collaborating to develop TSRA-196, a gene therapy aimed at treating alpha-1 antitrypsin deficiency (AATD), which affects the lungs and liver. The main aim of the therapy is to treat the underlying gene mutation, and Tessera also has plans to seek regulatory approvals from clinical trials by year-end.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is an American biotech company that specializes in innovative medicines and treatments.

While we acknowledge the potential of REGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 15 Blue Chip Dividend Stocks to Build a Passive Income Portfolio and 15 Dividend Stocks That Outperform the S&P 500.

Disclosure: None.